Cystic fibrosis is characterized by an overly exuberant neutrophilic inflammatory response to pathogens and other stimuli that starts very early in disease. The overwhelming nature of this response is a primary cause of remodeling and destruction of the airways, suggesting that anti-inflammatory therapies could be beneficial in CF.
| Origins of CF inflammation
A key finding of studies of early CF lung disease is that airway inflammation begins at or very soon after birth. Neutrophils and neutrophil elastase can be detected in bronchoalveolar lavage (BAL) in patients diagnosed with CF by newborn screen as early as 3 months of age, and these inflammatory markers correlate with future development of bronchiectasis and gas trapping on CT scan. 1 This increase in inflammation does not appear to be solely a response to infection, since less than half of infants with neutrophil elastase detected in BAL fluid had an active pulmonary infection or history suggesting infection. These observations suggest that inflammation in CF airways is multifactorial ( Fig. 1 ) and can occur even in the absence of an infectious stimulus.
Localized hypoxia in the CF lung could explain the early inflammation seen in the absence of obvious infection. 3 The gene mutated in CF, the cystic fibrosis transmembrane conductance regulator (CFTR), encodes a cAMP dependent anion channel that conducts chloride and bicarbonate and regulates the balance of chloride secretion and sodium absorption in the airway. 4 Loss of CFTR channel activity produces a dehydrated airway surface environment where the total mass of salt and volume of water are inadequate to maintain mucus hydration, leading to defects in mucociliary clearance.
The resulting thickened mucus and mucus plugging in the small airway create localized areas of hypoxia, which can trigger inflammatory responses 5 including release of cytokines such as IL-1 and activation of the inflammatory cascade via binding to the IL-1 receptor. 6 The resultant increase in inflammation may then worsen hypoxia and contribute to a niche for anaerobic bacteria, thus further propagating the inflammatory cycle. The mucus dehydration and impaired mucociliary clearance contribute to enhanced inflammatory responses, with failure to clear pathogens out of the airway leading to prolonged stimulation of inflammatory pathways. 8, 9 Furthermore, there is evidence that CFTR may play a more direct role in regulation of inflammatory responses.
For example, neutrophils isolated from patients with CF tend to undergo necrotic rather than apoptotic responses, releasing additional pro-inflammatory molecules such as High Mobility Group Box 1 (HMGB1) protein and metalloproteases. 10, 11 There is also evidence that CFTR is involved in the acidification of phagosomes and bacterial killing in both neutrophils and macrophages. 12, 13 Similarly, CF macrophages and monocytes also demonstrate defective immune response. 
| Anti-inflammatory therapies in CF
Although the factors that contribute to inflammation in CF are not fully defined, the relevance of inflammation as a therapeutic target is unquestioned. 23 Nevertheless, despite intensive effort, limited therapies are available. Prednisone is perhaps the most canonical antiinflammatory, and alternate day therapy with prednisone has been shown to increase forced vital capacity (FVC) in treated CF patients compared to placebo. 24 However, chronic use of systemic steroids is contraindicated due to their adverse effects including growth retardation, osteoporosis, cataracts, hyperglycemia and risk of opportunistic infection. High dose ibuprofen is a more targeted antiinflammatory that has been shown to slow the rate of decline of FEV 1 in two separate double blind, placebo controlled studies, 25, 26 and this clinical benefit has been associated with a decrease in neutrophil migration to the lung. 27 Although trials with ibuprofen did not show a significant increase in adverse events between treatment and placebo groups, the perceived risk of gastrointestinal bleeding and renal toxicity coupled with the need to obtain serum levels to minimize these risks has inhibited widespread use of this drug.
The most widely used therapy in CF with anti-inflammatory properties is azithromycin. Interest in azithromycin as a CF therapeutic stemmed from its benefit in diffuse panbronchiolitis, 28 a disease with many similarities to CF, and was thought to possibly relate to its antimicrobial activity against Pseudomonas aeruginosa growing in biofilms. 29 Indeed, the initial large study of chronic, low dose azithromycin in CF was targeted towards patients with persistent
Pseudomonas infection. This study demonstrated that chronic azithromycin treatment led to improvement in FEV 1 , a decrease in exacerbations requiring antibiotic therapy, as well as improved quality of life (QOL) scores. 30, 31 However, the clinical benefits occurred despite minimal impact on Pseudomonas bacterial density, suggesting that a different mechanism of action was responsible. Azithromycin has a number of anti-inflammatory effects, including reduction in neutrophil oxidative burst and increases neutrophil apoptosis. 32, 33 In lung macrophages azithromycin also appears to inhibit apoptosis, stimulate phagocytosis of bacteria and cellular debris, as well as skew macrophage cytokine expression toward an anti-inflammatory phenotype. 34 Other anti-inflammatory effects of azithromycin include decreased mucin production with a resultant decrease in mucus viscosity, maintenance of tight junctions between epithelial cells and improvement of the integrity of the epithelial cell layer under inflammatory conditions. 33 These immunomodulatory effects may receptor known to play a significant role in CF airway inflammation.
This trial was stopped early due to an increase in pulmonary adverse events in those receiving the active drug compared to placebo. 36 Further studies showed that treatment of CF mice with BIIL 284 BS interfered with their ability to resolve Pseudomonas aeruginosa respiratory infection. 37 These results showcase the difficulty of balancing a reduction in inflammation while not significantly increasing the bacterial burden with the use of anti-inflammatory therapies and emphasize the need for pre-clinical testing of novel therapeutics. This need is particularly great in young children to try and limit inflammation before the onset of lung damage. The challenges in developing better biomarkers reflect limitations in the primary methods to obtain airway samples: sputum collection, bronchoalveolar lavage, and assessments of exhaled breath ( Fig. 2 and Table 1 ).
| Sputum
Historically, assessments of airway inflammation in CF (and other diseases) have been primarily based on analysis of biomarkers in sputum, in part reflecting the long experience and existence of standardized protocols for this airway sample. Given the intense airway inflammation that characterizes CF, it is no surprise that a multitude of inflammatory biomarkers are elevated in CF sputum, as summarized in several excellent reviews. 2, 40 Among these biomarkers, sputum neutrophil elastase has emerged as one of the most predictive, with concentrations of sputum NE most highly correlated with lung function decline in large studies.
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However, the utility of sputum is limited somewhat by the need for specialized procedures to process samples that typically must be performed immediately after collection. 43 Spontaneously expectorated sputum likely arises from more affected regions of the lung, and concentrations of inflammatory markers can be influenced by regional variability in lung disease 39 Furthermore, in general only older patients with more advanced disease can regularly expectorate sputum spontaneously. While sputum induction using hypertonic saline can be utilized to obtain samples from patients who do not spontaneously expectorate, many younger children have difficulty expectorating sputum even after induction. 44, 45 Thus, sputum has a limited role in assessing-and by extension treating-airway inflammation in the youngest children.
| Bronchoalveolar lavage fluid
For patients who cannot expectorate sputum, flexible bronchoscopy with BAL is considered the gold standard for airway biomarker assessment. 40 As with sputum, numerous inflammatory biomarkers are elevated in BAL fluid in children with CF including neutrophil counts, neutrophil elastase, pro-inflammatory cytokines such as interleukin-8, and others. 46 69, 70 EBC pH has also been shown to be decreased in subjects with CF and change with treatment of an exacerbation. [71] [72] [73] With specialized methods, EBC can even be collected from the youngest children during infant pulmonary function testing (iPFTs).
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The ease of EBC collection is belied by difficulty in analysis, with EBC being described as "easy on patients" but "hard on scientists." 77 Airway secretions in EBC arise from microaerosols generated during respiration, which represent a very low and highly variable fraction of the fluid volume of the condensate and may under-sample obstructed airways. 78, 79 Therefore, extremely sensitive methods are typically needed to assess the low concentrations of most traditional biomarkers found in EBC, which ideally should also include a means to control for variable dilution. 78, 80 Our own approach has been to utilize mass spectrometry to measure relevant biomarkers as well as urea as a dilution marker, [81] [82] [83] though there are other valid methods. 30, 32 Failure to adequately address these challenges impacts the reproducibility and validity of EBC biomarkers and may limit their utility as effective measures of airway inflammation. 84 Some of the limitations of EBC can be addressed by a focus on volatile biomarkers, which are not dependent on microaerosol generation for incorporation in exhaled breath. Several studies had
shown that volatile organic carbon (VOC) profiles are altered in individuals with CF and could serve as inflammatory biomarkers. 85, 86 One of the potentially exciting application of VOC profiling in CF is the development of electronic "nose" systems that could provide information on airway inflammation at the point of care. 87, 88 However, current methods require sophisticated mathematical modeling to identify complex patterns in the detected VOCs, and the reproducibility of these signatures and their relationships to specific aspects of airway inflammation have not been established.
| Non airway samples
The high levels of inflammation in the airways of individuals with CF translate into increases in systemic inflammatory biomarkers that could be assessed in serum or plasma, which are relatively easily obtained and analyze. Indeed, a large number of blood inflammatory markers are elevated relative in CF, including C-reactive protein, [89] [90] [91] [92] immunoglobulin G, 90, 93, 94 cytokines, 91 tumor necrosis factor, 95 and transforming growth factor β, 96 many of which are altered with pulmonary exacerbation. 91, 92, 96, 97 However, the potential contribution of non-pulmonary inflammation reduces the specificity of these biomarker for lung disease and limits applicability. There have also been small trials investigating the use of biomarkers in both saliva and urine as a surrogate for lung inflammation. Patients underwent FDG PET on days 1 and 14 of treatment and degree of inflammation was determined using standard uptake values (SUV). This group found that over the course of 14 days of IV therapy the max SUV decreased. 101 Regular use of FDG PET CT is limited by radiation exposure, however, as low dose CT protocols improve this may become a useful technique to follow lung inflammation.
| Novel strategies
Despite all we have learned about the inflammatory pathways involved in CF lung disease, numerous challenges remain in translating these Table 2) .
Use of 'omics strategies, particularly metabolomics, is well suited towards identifying pathways that meet these criteria. The changes in metabolite patterns associated with disease reflect cellular enzymatic activities, which are attractive as therapeutic targets since they can often be inhibited by small molecule therapeutics. 103 Furthermore, the identified metabolites can serve as biomarkers of pathway activity and drug effects, many of which can be readily measured using standard methods even in non-invasive sample such as EBC. 81, 82, 104 The potential metabolomics has been demonstrated in several studies that find CF specific metabolite patterns in sputum, 105 BALF, [106] [107] [108] blood, 109, 110 and even EBC. 111, 112 Metabolomics studies can be particularly informative when interpreted in conjunction with other 'omics evaluations. For example, one of the largest gene wide association studies to date in CF identified associations between disease severity and expression of the gene APIP, 113 which encodes an enzyme involved in the methionine salvage pathway, and metabolites associated with this pathway, including polyamines and free adenine, are associated with neutrophilic inflammation in CF. 107, 108, 114 Similarly, the lysophosphatidic acid receptor LPAR6 has been linked to CF lung disease in genomic studies, 115 while the lysophospholipid substrates of this receptor are elevated in CF bronchitis. 107, 116 While such studies demonstrate the promise of metabolomics to identify biomarkers and therapeutic targets, further study is needed before the potential of these identified pathways is truly known.
| CONCLUSIONS
The intense inflammation present in the airways of individuals with CF is one of the most significant causes of progressive lung disease. Until we have a cure for CF, development of effective anti-inflammatories needs to be a priority for the CF research community. New approaches using metabolomics and other strategies to map the inflammatory targets in CF hold promise in development of new therapies.
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